High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$147K
$147,421
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-02-11
$8,153
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-02-11 | $8,153 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-01-22
$73,371
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-01-22 | $73,371 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-01-20
$26,404
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-01-20 | $26,404 | S | Form 4 |
|
APLS
S
Apellis Pharmaceuticals, Inc.
DeLong Mark Jeffrey
• Officer • Chief Business & Strat Officer
Sell to Cover
2026-01-13
$39,493
|
||||||
| APLS |
Apellis Pharmaceuticals, Inc.
|
Officer • Chief Business & Strat Officer
Sell to Cover
|
2026-01-13 | $39,493 | S | Form 4 |